Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,571–1,580 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1571
- Medicine slug
- treprostinil
- Compared field
- bioavailability
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 6
- Source count
- 4
- Agreement rate
- 0.5
- Recorded readings
100%
- Numeric value
- 100
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a684b13-669d-4721-8ed4-30cc7762b0b8 (opens source in a new tab)
Treprostinil label
Version not recorded · Effective date not recorded
Absorption Treprostinil injection is relatively rapidly and completely absorbed after subcutaneous infusion, with an absolute bioavailability approximating 100%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b2ce4aa-4302-49db-9456-c8cf0e034968 (opens source in a new tab)
Treprostinil label
Version not recorded · Effective date not recorded
Ab sorption Treprostinil is relatively rapidly and completely absorbed after subcutaneous infusion, with an absolute bioavailability approximating 100%.
17%
- Numeric value
- 17
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ed2003a-c801-411e-831e-d06079bb0d7c (opens source in a new tab)
Treprostinil label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of Orenitram is approximately 17%.
64%
- Numeric value
- 64
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbc31ab1-a80f-4b50-a3b1-39910b0fb609 (opens source in a new tab)
Treprostinil label
Version not recorded · Effective date not recorded
Mean estimates of the absolute systemic bioavailability of treprostinil after inhalation were approximately 64% (18 mcg) and 72% (36 mcg).
Projected row 1572
- Medicine slug
- treprostinil
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 6
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
4 hours
- Numeric value
- 4
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbc31ab1-a80f-4b50-a3b1-39910b0fb609 (opens source in a new tab)
Treprostinil label
Version not recorded · Effective date not recorded
The elimination of treprostinil (following subcutaneous administration of treprostinil) is biphasic, with a terminal elimination half-life of approximately 4 hours using a 2-compartment model.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a684b13-669d-4721-8ed4-30cc7762b0b8 (opens source in a new tab)
Treprostinil label
Version not recorded · Effective date not recorded
The elimination of treprostinil (following subcutaneous administration) is biphasic, with a terminal elimination half-life of approximately 4 hours using a two compartment model.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b2ce4aa-4302-49db-9456-c8cf0e034968 (opens source in a new tab)
Treprostinil label
Version not recorded · Effective date not recorded
The elimination of treprostinil (following subcutaneous administration) is biphasic, with a terminal elimination half-life of approximately 4 hours using a two-compartment model.
Projected row 1573
- Medicine slug
- treprostinil
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 6
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
14 L
- Numeric value
- 14
- Unit
- L
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbc31ab1-a80f-4b50-a3b1-39910b0fb609 (opens source in a new tab)
Treprostinil label
Version not recorded · Effective date not recorded
Distribution Following parenteral infusion, the apparent steady state volume of distribution (V ss ) of treprostinil is approximately 14 L/70 kg ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ddc3d400-bcb3-4b09-aae2-0768b10a5b0f (opens source in a new tab)
Treprostinil label
Version not recorded · Effective date not recorded
Distribution Following parenteral infusion, the steady state volume of distribution (V ss ) of treprostinil is approximately 14 L/70 kg ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a684b13-669d-4721-8ed4-30cc7762b0b8 (opens source in a new tab)
Treprostinil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of the drug in the central compartment is approximately 14 L/70 kg ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b2ce4aa-4302-49db-9456-c8cf0e034968 (opens source in a new tab)
Treprostinil label
Version not recorded · Effective date not recorded
D i stribution The volume of distribution of the drug in the central compartment is approximately 14 L/70 kg ideal body weight.
Projected row 1574
- Medicine slug
- tretinoin
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 58
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
50%
- Numeric value
- 50
- Unit
- %
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:264138c1-9e5f-45ef-be87-79ca97c989d9 (opens source in a new tab)
Tretinoin (topical) label
Version not recorded · Effective date not recorded
The absolute bioavailability of tretinoin capsules was approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c4ae9d9-c2a0-4995-a27a-e3f0f0284db9 (opens source in a new tab)
Tretinoin (topical) label
Version not recorded · Effective date not recorded
The absolute bioavailability of tretinoin capsules was approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a7974c7-8b6c-41ae-9a48-a08a1439087a (opens source in a new tab)
Tretinoin (topical) label
Version not recorded · Effective date not recorded
The absolute bioavailability of tretinoin capsules was approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b22d5a07-623a-4645-b87d-a151b86da8d5 (opens source in a new tab)
Tretinoin (topical) label
Version not recorded · Effective date not recorded
The absolute bioavailability of tretinoin capsules was approximately 50%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:045258e2-5efb-4147-bf74-4c43af04dccc (opens source in a new tab)
Tretinoin (topical) label
Version not recorded · Effective date not recorded
The absolute bioavailability of tretinoin capsules was approximately 50%.
Projected row 1575
- Medicine slug
- tretinoin
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 58
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
0.5 to 2 hours
- Numeric value
- 0.5
- Unit
- hours
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:264138c1-9e5f-45ef-be87-79ca97c989d9 (opens source in a new tab)
Tretinoin (topical) label
Version not recorded · Effective date not recorded
Elimination The terminal elimination half-life of tretinoin following initial dosing is 0.5 to 2 hours in patients with APL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c4ae9d9-c2a0-4995-a27a-e3f0f0284db9 (opens source in a new tab)
Tretinoin (topical) label
Version not recorded · Effective date not recorded
Elimination The terminal elimination half-life of tretinoin following initial dosing is 0.5 to 2 hours in patients with APL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a7974c7-8b6c-41ae-9a48-a08a1439087a (opens source in a new tab)
Tretinoin (topical) label
Version not recorded · Effective date not recorded
Elimination The terminal elimination half-life of tretinoin following initial dosing is 0.5 to 2 hours in patients with APL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b22d5a07-623a-4645-b87d-a151b86da8d5 (opens source in a new tab)
Tretinoin (topical) label
Version not recorded · Effective date not recorded
Elimination The terminal elimination half-life of tretinoin following initial dosing is 0.5 to 2 hours in patients with APL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:045258e2-5efb-4147-bf74-4c43af04dccc (opens source in a new tab)
Tretinoin (topical) label
Version not recorded · Effective date not recorded
Elimination The terminal elimination half-life of tretinoin following initial dosing is 0.5 to 2 hours in patients with APL.
Projected row 1576
- Medicine slug
- tretinoin
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 58
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
95%
- Numeric value
- 95
- Unit
- %
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:264138c1-9e5f-45ef-be87-79ca97c989d9 (opens source in a new tab)
Tretinoin (topical) label
Version not recorded · Effective date not recorded
Protein binding is greater than 95%, predominately to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c4ae9d9-c2a0-4995-a27a-e3f0f0284db9 (opens source in a new tab)
Tretinoin (topical) label
Version not recorded · Effective date not recorded
Protein binding is greater than 95%, predominately to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a7974c7-8b6c-41ae-9a48-a08a1439087a (opens source in a new tab)
Tretinoin (topical) label
Version not recorded · Effective date not recorded
Protein binding is greater than 95%, predominately to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b22d5a07-623a-4645-b87d-a151b86da8d5 (opens source in a new tab)
Tretinoin (topical) label
Version not recorded · Effective date not recorded
Protein binding is greater than 95%, predominately to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:045258e2-5efb-4147-bf74-4c43af04dccc (opens source in a new tab)
Tretinoin (topical) label
Version not recorded · Effective date not recorded
Protein binding is greater than 95%, predominately to albumin.
Projected row 1577
- Medicine slug
- triamcinolone-acetonide
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 213
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
76 to 635 hours
- Numeric value
- 76
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2267978c-72ad-9229-e063-6394a90a09d0 (opens source in a new tab)
Triamcinolone Acetonide label
Version not recorded · Effective date not recorded
Peak aqueous humor concentrations of triamcinolone ranged from 2151 to 7202 ng/mL, half-life 76 to 635 hours, and the area under the concentration-time curve (AUC 0-t ) from 231 to 1911 ng.h/mL following the single intravitreal administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22692d92-1359-9252-e063-6394a90ab669 (opens source in a new tab)
Triamcinolone Acetonide label
Version not recorded · Effective date not recorded
Peak aqueous humor concentrations of triamcinolone ranged from 2151 to 7202 ng/mL, half-life 76 to 635 hours, and the area under the concentration-time curve (AUC 0-t ) from 231 to 1911 ng.h/mL following the single intravitreal administration.
Projected row 1578
- Medicine slug
- triazolam
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 9
- Agreement rate
- 1
- Recorded readings
1.5 to 5.5 hours
- Numeric value
- 1.5
- Unit
- hours
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97164a9c-4bc7-4f15-829e-5f9e653c7fa5 (opens source in a new tab)
Triazolam label
Version not recorded · Effective date not recorded
CLINICAL PHARMACOLOGY Triazolam is a hypnotic with a short mean plasma half-life reported to be in the range of 1.5 to 5.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d414eb8-eec9-486f-90fc-00eed0cf7daf (opens source in a new tab)
Triazolam label
Version not recorded · Effective date not recorded
Elimination Triazolam has a mean plasma elimination half-life in the range of 1.5 to 5.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba1d8955-41f8-4b4d-8ed8-e92667e294a1 (opens source in a new tab)
Triazolam label
Version not recorded · Effective date not recorded
Elimination Triazolam has a mean plasma elimination half-life in the range of 1.5 to 5.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5add318e-11b9-42f8-b052-0d8cebb32fcf (opens source in a new tab)
Triazolam label
Version not recorded · Effective date not recorded
Elimination Triazolam has a mean plasma elimination half-life in the range of 1.5 to 5.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8ca4773-e201-4cb9-8869-5ee07ba1d0bf (opens source in a new tab)
Triazolam label
Version not recorded · Effective date not recorded
Elimination Triazolam has a mean plasma elimination half-life in the range of 1.5 to 5.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0c99f0b-4122-4611-9b53-80fadfceacb6 (opens source in a new tab)
Triazolam label
Version not recorded · Effective date not recorded
Elimination Triazolam has a mean plasma elimination half-life in the range of 1.5 to 5.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a96c618-1869-4cb6-b9f3-549e8581af72 (opens source in a new tab)
Triazolam label
Version not recorded · Effective date not recorded
Elimination Triazolam has a mean plasma elimination half-life in the range of 1.5 to 5.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5fccc31d-32c9-49e7-91a9-664cc726872b (opens source in a new tab)
Triazolam label
Version not recorded · Effective date not recorded
Elimination Triazolam has a mean plasma elimination half-life in the range of 1.5 to 5.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a330f08-5d8f-4f8d-8847-a45b734412b4 (opens source in a new tab)
Triazolam label
Version not recorded · Effective date not recorded
Elimination Triazolam has a mean plasma elimination half-life in the range of 1.5 to 5.5 hours.
Projected row 1579
- Medicine slug
- trilaciclib
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
14 hours
- Numeric value
- 14
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3179c19-78f3-4bf1-b73e-7f7638522ab1 (opens source in a new tab)
Trilaciclib label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life of trilaciclib is approximately 14 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b06922c-498d-4871-a037-84a44e6a6b6c (opens source in a new tab)
Trilaciclib label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life of trilaciclib is approximately 14 hours.
Projected row 1580
- Medicine slug
- trilaciclib
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
69%
- Numeric value
- 69
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3179c19-78f3-4bf1-b73e-7f7638522ab1 (opens source in a new tab)
Trilaciclib label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of trilaciclib is 69% and appeared independent of trilaciclib concentration from 0.75 to 3.0 μg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b06922c-498d-4871-a037-84a44e6a6b6c (opens source in a new tab)
Trilaciclib label
Version not recorded · Effective date not recorded
Distribution The in vitro human plasma protein binding of trilaciclib is 69% and appeared independent of trilaciclib concentration from 0.75 to 3.0 μg/mL.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1570Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.